34 related articles for article (PubMed ID: 32224192)
1. Microparticles and cardiotoxicity secondary to doxorubicin-based chemotherapy in breast cancer patients.
Pestana RMC; Teixeira-Carvalho A; Dos Santos LI; de Oliveira AN; Soares CE; Sabino AP; Simões R; Gomes KB
Int J Cardiol; 2024 Jan; 395():131435. PubMed ID: 37852542
[TBL] [Abstract][Full Text] [Related]
2. The sGCa Vericiguat Exhibit Cardioprotective and Anti-Sarcopenic Effects through NLRP-3 Pathways: Potential Benefits for Anthracycline-Treated Cancer Patients.
Quagliariello V; Berretta M; Bisceglia I; Giacobbe I; Iovine M; Giordano V; Arianna R; Barbato M; Izzo F; Maurea C; Canale ML; Paccone A; Inno A; Scherillo M; Gabrielli D; Maurea N
Cancers (Basel); 2024 Apr; 16(8):. PubMed ID: 38672567
[TBL] [Abstract][Full Text] [Related]
3. Co-growth of Stem Cells With Target Tissue Culture as an Easy and Effective Method of Directed Differentiation.
Kovina MV; Dyuzheva TG; Krasheninnikov ME; Yakovenko SA; Khodarovich YM
Front Bioeng Biotechnol; 2021; 9():591775. PubMed ID: 34222206
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin-induced p53 interferes with mitophagy in cardiac fibroblasts.
Mancilla TR; Davis LR; Aune GJ
PLoS One; 2020; 15(9):e0238856. PubMed ID: 32960902
[TBL] [Abstract][Full Text] [Related]
5. Endothelial-to-Mesenchymal Transition: Potential Target of Doxorubicin-Induced Cardiotoxicity.
Feng J; Wu Y
Am J Cardiovasc Drugs; 2023 May; 23(3):231-246. PubMed ID: 36841924
[TBL] [Abstract][Full Text] [Related]
6. Role of non-cardiomyocytes in anticancer drug-induced cardiotoxicity: A systematic review.
Xie S; Yang Y; Luo Z; Li X; Liu J; Zhang B; Li W
iScience; 2022 Nov; 25(11):105283. PubMed ID: 36300001
[TBL] [Abstract][Full Text] [Related]
7. Transient Exposure of Endothelial Cells to Doxorubicin Leads to Long-Lasting Vascular Endothelial Growth Factor Receptor 2 Downregulation.
Graziani S; Scorrano L; Pontarin G
Cells; 2022 Jan; 11(2):. PubMed ID: 35053325
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular ramifications of therapy-induced endothelial cell senescence in cancer survivors.
Abdelgawad IY; Agostinucci K; Zordoky BN
Biochim Biophys Acta Mol Basis Dis; 2022 Apr; 1868(4):166352. PubMed ID: 35041996
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms and cardiovascular implications of cancer therapy-induced senescence.
Abdelgawad IY; Sadak KT; Lone DW; Dabour MS; Niedernhofer LJ; Zordoky BN
Pharmacol Ther; 2021 May; 221():107751. PubMed ID: 33275998
[TBL] [Abstract][Full Text] [Related]
10. The novel butyrate derivative phenylalanine-butyramide protects from doxorubicin-induced cardiotoxicity.
Russo M; Guida F; Paparo L; Trinchese G; Aitoro R; Avagliano C; Fiordelisi A; Napolitano F; Mercurio V; Sala V; Li M; Sorriento D; Ciccarelli M; Ghigo A; Hirsch E; Bianco R; Iaccarino G; Abete P; Bonaduce D; Calignano A; Berni Canani R; Tocchetti CG
Eur J Heart Fail; 2019 Apr; 21(4):519-528. PubMed ID: 30843309
[TBL] [Abstract][Full Text] [Related]
11. Metabolic Aspects of Anthracycline Cardiotoxicity.
Russo M; Della Sala A; Tocchetti CG; Porporato PE; Ghigo A
Curr Treat Options Oncol; 2021 Feb; 22(2):18. PubMed ID: 33547494
[TBL] [Abstract][Full Text] [Related]
12. The Interplay Between Autophagy and Senescence in Anthracycline Cardiotoxicity.
Russo M; Bono E; Ghigo A
Curr Heart Fail Rep; 2021 Aug; 18(4):180-190. PubMed ID: 34081265
[TBL] [Abstract][Full Text] [Related]
13. Distinct influence of the anthracycline derivative doxorubicin on the differentiation efficacy of mESC-derived endothelial progenitor cells.
Jahn SK; Hennicke T; Kassack MU; Drews L; Reichert AS; Fritz G
Biochim Biophys Acta Mol Cell Res; 2020 Jul; 1867(7):118711. PubMed ID: 32224192
[TBL] [Abstract][Full Text] [Related]
14. mESC-based in vitro differentiation models to study vascular response and functionality following genotoxic insults.
Hennicke T; Nieweg K; Brockmann N; Kassack MU; Gottmann K; Fritz G
Toxicol Sci; 2015 Mar; 144(1):138-50. PubMed ID: 25516496
[TBL] [Abstract][Full Text] [Related]
15. Folic acid reduces doxorubicin-induced cardiomyopathy by modulating endothelial nitric oxide synthase.
Octavia Y; Kararigas G; de Boer M; Chrifi I; Kietadisorn R; Swinnen M; Duimel H; Verheyen FK; Brandt MM; Fliegner D; Cheng C; Janssens S; Duncker DJ; Moens AL
J Cell Mol Med; 2017 Dec; 21(12):3277-3287. PubMed ID: 28608983
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
